Search
Research
Increased Body Mass Index during Therapy for Childhood Acute Lymphoblastic Leukemia: A Significant and Underestimated ComplicationWe undertook a retrospective review of children diagnosed with acute lymphoblastic leukemia (ALL) and treated with modern COG protocols to determine...
Research
The aggregation of early-onset melanoma in young Western Australian familiesResults indicated a strong familial basis of melanoma, with the higher than expected hazard ratio observed likely to reflect early-age at onset cases in this...
Research
Novel CT domain-encoding splice forms of CTGF/CCN2 are expressed in B-lineage acute lymphoblastic leukaemiaConnective tissue growth factor (CTGF/CCN2) has been shown previously to be aberrantly expressed in a high proportion of paediatric precursor B cell acute...
Research
The Australian and New Zealand Children's Haematology/Oncology Group Biobanking NetworkThe ANZCHOG-BN is a new biobank network in Australasia that was developed to improve and streamline access to high-quality pediatric and AYA cancer biospecimens
Research
Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skinOur results show that TRM cells have a fundamental role in the surveillance of subclinical melanomas in the skin by maintaining cancer-immune equilibrium
Research
Romidepsin enhances the efficacy of cytarabine in vivo, revealing HDAC inhibition as a therapeutic strategy for KMT2A-rearranged acute lymphoblastic leukemiaIn this study, we investigate the in vivo synergy between romidepsin and cytarabine
Research
Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemiaWe found two known risk factors in a large cohort of children treated for ALL and identified other factors associated with venous thromboembolism
Research
PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumoursOur findings define PTPN2 as a target for bolstering T-cell-mediated anti-tumour immunity and CAR T-cell therapy against solid tumours.
Research
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironmentOur results identify a pretreatment tumor microenvironment that predicts response to immune checkpoint blockade, which can be therapeutically attained
Research
Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigensThese findings suggest that tumor cells employ multiple epigenetic and genetic mechanisms to evade immune control